دورية أكاديمية
أعرض في EDS

Validation of the NIDA-modified ASSIST as a Screening Tool for Prenatal Drug Use in an Urban Setting in the United States.

التفاصيل البيبلوغرافية
العنوان: Validation of the NIDA-modified ASSIST as a Screening Tool for Prenatal Drug Use in an Urban Setting in the United States.
المؤلفون: Oga EA; RTI International, 6110 Executive Boulevard, Rockville, MD (EAO); Battelle Memorial Institute, Baltimore, MD (EAO, ENP, VHC-C); University of Maryland School of Medicine, Baltimore, MD (KM, VHC-C); The Emmes Company, LLC, Rockville, MD (VHC-C)., Mark K, Peters EN, Coleman-Cowger VH
المصدر: Journal of addiction medicine [J Addict Med] 2020 Sep/Oct; Vol. 14 (5), pp. 423-430.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101306759 Publication Model: Print Cited Medium: Internet ISSN: 1935-3227 (Electronic) Linking ISSN: 19320620 NLM ISO Abbreviation: J Addict Med Subsets: MEDLINE
أسماء مطبوعة: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Nitrosamines* , Pharmaceutical Preparations* , Substance-Related Disorders*/diagnosis , Substance-Related Disorders*/epidemiology, Female ; Humans ; Mass Screening ; Pregnancy ; Substance Abuse Detection ; United States/epidemiology
مستخلص: Background: Screening for prenatal drug use is recommended. The NIDA-modified Alcohol, Smoking, and Substance Involvement Screening Test (NM-ASSIST) is a screener for drug use that has not yet been validated with pregnant women. This study aims to assess the substance-specific diagnostic validity of the NM-ASSIST (not including tobacco or alcohol) in pregnant women and determine optimal cut-points for substance-specific substance involvement (SI) scores.
Methods: Five hundred (500) pregnant women were recruited from 2 obstetric practices as part of a larger study of substance use screeners. Participants completed the NM-ASSIST, and provided urine and hair samples for testing. Receiver-operating characteristic curves were derived to determine the optimal SI score cut-points for each drug.
Findings: Prevalence estimates of prenatal drug use as determined by hair/urine drug testing were: cannabis (32.0%), cocaine (9.9%), benzodiazepines (1.0%), prescription opioids (4.3%), and street opioids (1.7%). The proportion of participants screening positive based on optimal SI score cut-points were as follows: cannabis (39.1%), cocaine (2.3%), benzodiazepines (0.8%), prescription opioids (2.7%), and street opioids (1.7%). There were no screen positives for amphetamines, but 6 (1.2%) women had a positive amphetamine hair or urine test. Optimal cut-points to identify prenatal drug use were: cannabis, 2 (area under the curve [AUC] 0.87; sensitivity 0.82; specificity 0.85; diagnostic odds ratio [DOR] 26.9); cocaine, 2 (AUC 0.58; sensitivity 0.17; specificity 0.99; DOR 29.0); benzodiazepines, 15 (AUC 0.59; sensitivity 0.20; specificity 0.99; DOR 38.8); prescription opioids, 3 (AUC 0.61; sensitivity 0.25; specificity 0.98; DOR 18.3); and street opioids, 4 (AUC 0.55; sensitivity 0.13; specificity 0.99; DOR 9.3).
Conclusions: The NM-ASSIST reliably distinguished pregnant women who use cannabis from those who do not, but performed poorly for all other substances. More research is needed to identify screeners that reliably detect all prenatal drug use. Although more cost-prohibitive, a combination of self-report and toxicological screening may be preferable for detecting prenatal drug use.
References: SAMHSA. Results from the 2012 National Survey on Drug Use and Health: Summary of national findings. In: NSDUH Series H-46, HHS Publication No.(SMA) 13-4795. Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD; 2013.
Forray A. Substance use during pregnancy. F1000Res 2016; 5: doi: 10.12688/f1000research. (PMID: 10.12688/f1000research)
Coleman-Cowger VH, Oga EA, Peters EN, Trocin K, Koszowski B, Mark K. Comparison and validation of screening tools for substance use in pregnancy: a cross-sectional study conducted in Maryland prenatal clinics. BMJ Open 2018; 8:e020248.
Chasnoff I, Wells A, McGourty R, Bailey L. Validation of the 4P's Plus (screen for substance use in pregnancy validation of the 4P's Plus. J Perinatol 2007; 27 (12):744.
Oga EA, Peters EN, Mark K, Trocin K, Coleman-Cowger VH. Prenatal substance use and perceptions of parent and partner use using the 4P's Plus screener. Matern Child Health J 2019; 23 (2):250–257.
Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale. Obstet Gynecol 2010; 116 (4):827.
NIDA. Smoking, and Substance Involvement Screening Test: NM-ASSIST. Available at: https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf. Accessed November 28, 2019.
WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002; 97 (9):1183–1194.
Midanik LT. Validity of self-reported alcohol use: a literature review and assessment. Br J Addict 1988; 83 (9):1019–1029.
Zuckerman B, Amaro H, Cabral H. Validity of self-reporting of marijuana and cocaine use among pregnant adolescents. J Pediatr 1989; 115 (5):812–815.
Garg M, Garrison L, Leeman L, et al. Validity of self-reported drug use information among pregnant women. Matern Child Health J 2016; 20 (1):41–47.
Kelly RH, Zatzick DF, Anders TF. The detection and treatment of psychiatric disorders and substance use among pregnant women cared for in obstetrics. Am J Psychiatry 2001; 158 (2):213–219.
McNeely J, Strauss SM, Wright S, et al. Test–retest reliability of a self-administered Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary care patients. J Subst Abuse Treat 2014; 47 (1):93–101.
McNeely J, Wu L-T, Subramaniam G, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med 2016; 165 (10):690–699.
NIDA. Tobacco, Alcohol, Prescription medication, and other Substance use Tool (TAPS). Available at: https://www.drugabuse.gov/taps/#/. Accessed August 6, 2018.
Chang G, Ondersma SJ, Blake-Lamb T, Gilstad-Hayden K, Orav EJ, Yonkers KA. Identification of substance use disorders among pregnant women: a comparison of screeners. Drug Alcohol Depend 2019; 205:107651.
Ondersma SJ, Chang G, Blake-Lamb T, et al. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction 2019; 114:1683–1693.
Coleman-Cowger VH, Oga EA, Peters EN, Trocin KE, Koszowski B, Mark K. Accuracy of three screening tools for prenatal substance use. Obstet Gynecol 2019; 133 (5):952.
Trocin KE, Weinstein NI, Oga EA, Mark KS, Coleman-Cowger VH. Prenatal practice staff perceptions of three substance use screening tools for pregnant women. J Addict Med 2019; doi: 10.1097/ADM.0000000000000543 [Epub ahead of print]. (PMID: 10.1097/ADM.0000000000000543)
Oga EA, Mark K, Coleman-Cowger VH. Cigarette smoking status and substance use in pregnancy. Matern Child Health J 2018; 22:1477–1483.
Coleman-Cowger VH, Oga E, Peters EN, Mark K. Prevalence and associated birth outcomes of co-use of Cannabis and tobacco cigarettes during pregnancy. Neurotoxicol Teratol 2018; 68:84–90.
DuPont RL, Baumgartner WA. Drug testing by urine and hair analysis: complementary features and scientific issues. Forensic Sci Int 1995; 70 (1-3):63–76.
Ledgerwood DM, Goldberger BA, Risk NK, Lewis CE, Price RK. Comparison between self-report and hair analysis of illicit drug use in a community sample of middle-aged men. Addict Behav 2008; 33 (9):1131–1139.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56 (11):1129–1135.
Šimundić A-M. Measures of diagnostic accuracy: basic definitions. Ejifcc 2009; 19:203.
Newcombe DA, Humeniuk RE, Ali R. Validation of the world health organization alcohol, smoking and substance involvement screening test (ASSIST): report of results from the Australian site. Drug Alcohol Rev 2005; 24 (3):217–226.
Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29 (7):1043–1051.
Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA's Annual Mental Health, Substance Use Data Provide Roadmap for Future Action. Available at: https://www.hhs.gov/about/news/2018/09/14/samhsa-annual-mental-health-substance-use-data-provide-roadmap-for-future-action.html. Published 2018. Accessed November 28, 2019.
Ahrnsbrak R, Bose J, Hedden S, Lipari R, Park-Lee E. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration (SAMHSA) NSDUH Data Review. Available at: https://wwwsamhsagov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016htm Published September 2017. 2017.
Saitman A, Park H-D, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38 (7):387–396.
Roberts SC, Nuru-Jeter A. Women's perspectives on screening for alcohol and drug use in prenatal care. Womens Health Issues 2010; 20 (3):193–200.
Yonkers KA, Howell HB, Gotman N, Rounsaville BJ. Self-report of illicit substance use versus urine toxicology results from at-risk pregnant women. J Subst Use 2011; 16 (5):372–380.
Weatherby NL, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plan 1994; 17 (4):347–355.
Harrison L, Hughes A. The validity of self-reported drug use: Improving the accuracy of survey estimates. NIDA Res Monogr 1997; 167:1–16.
Christmas JT, Knisely JS, Dawson KS, Dinsmoor MJ, Weber SE, Schnoll SH. Comparison of questionnaire screening and urine toxicology for detection of pregnancy complicated by substance use. Obstet Gynecol 1992; 80 (5):750–754.
معلومات مُعتمدة: R01 DA041328 United States DA NIDA NIH HHS
المشرفين على المادة: 0 (Nitrosamines)
0 (Pharmaceutical Preparations)
25081-31-6 (N-nitrosoiminodiacetic acid)
تواريخ الأحداث: Date Created: 20200208 Date Completed: 20210624 Latest Revision: 20210903
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7415506
DOI: 10.1097/ADM.0000000000000614
PMID: 32032210
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-3227
DOI:10.1097/ADM.0000000000000614